Tamoxifen Citrate 20mg/tab 50 Tablets by Hilma Biocare

Usage

1. Confirm cycle clearance.: Calculate the washout period based on the longest ester used (e.g., ~5 half-lives for Testosterone Enanthate ≈ 21 days) before initiating any PCT agent to avoid SERM-androgen overlap that blunts gonadotrophin response.
2. Complete HCG priming first.: Administer HCG during the washout window to restore Leydig cell sensitivity before Tamoxifen Citrate is introduced; this two-stage approach is standard in heavy-cycle recovery frameworks.
3. Begin induction at 40 mg per day.: Take two 20 mg Hilma Biocare tablets simultaneously each morning with water, at the same time daily, starting the day after HCG is discontinued.
4. Step down to 20 mg per day at week three.: Reduce to one tablet per day; maintain consistent morning timing to stabilise plasma Tamoxifen levels, which reach steady state within approximately seven days of consistent dosing.
5. Monitor gonadotrophin response at the midpoint.: An LH, FSH, and total testosterone panel at week four of the SERM phase provides objective data on recovery trajectory and informs whether the planned taper timing remains appropriate.
6. Complete a four-week post-PCT bloodwork panel.: Final laboratory assessment of testosterone, LH, FSH, and oestradiol confirms axis restoration and identifies any residual deficiency requiring further clinical evaluation.

Warnings

Frequently asked questions

What makes PCT after a heavy AAS cycle fundamentally different from a standard recovery protocol?

Heavy-cycle suppression is deeper and longer-lasting because extended exposure to potent androgens progressively reduces pituitary gonadotroph sensitivity. Recovery timelines therefore extend to eight to twelve weeks, induction doses are higher, and the protocol often requires an HCG priming phase before SERM introduction — structural differences that a short three-to-four-week SERM course cannot adequately address.

When should HCG be used before starting Tamoxifen Citrate after a heavy cycle?

HCG is typically introduced in the two-to-four weeks immediately following the last AAS injection, before Tamoxifen Citrate begins. Its purpose is to restore Leydig cell responsiveness that heavy suppression has diminished. Once HCG is discontinued, Tamoxifen Citrate SERM therapy is initiated to drive pituitary LH and FSH output and sustain the testicular reactivation that HCG priming initiated.

How long does HPTA recovery realistically take after a long-term or multi-compound cycle?

Clinical data indicates that after cycles lasting sixteen or more weeks with highly suppressive compounds, full endogenous testosterone normalisation may take three to six months even with structured PCT. Active SERM therapy with Tamoxifen Citrate occupies the first eight to twelve weeks of this window, accelerating pituitary recovery; residual Leydig cell restoration continues beyond the SERM-active phase.

Why is the 20 mg per tablet dose the most practical option for heavy-cycle induction?

At 20 mg per tablet — the highest unit dose in this tablet range — a 40 mg induction day requires only two whole tablets, eliminating the splitting and measurement inaccuracies that arise when using lower-denomination tablets to achieve the same daily dose. During the taper phase, a single tablet delivers the 20 mg maintenance dose with no adjustment needed, keeping the protocol straightforward throughout.

Does the 50-tablet pack provide enough supply for a full intensive heavy-cycle PCT?

Yes. A representative heavy-cycle protocol — for example, 40 mg per day for four weeks followed by 20 mg per day for four weeks — consumes exactly 50 tablets over the eight-week SERM-active phase. Because Hilma Biocare's pack count matches this consumption exactly, the supply is exhausted at protocol completion with no excess tablets and no need for a second order mid-protocol. (2) angle_used

Manufacturer

Hilma Biocare's finished-product release framework for Tamoxifen Citrate 20mg/tab is structured around a presentation-specific documentation chain that begins at the raw material stage and terminates only when the sealed blister pack satisfies all compound-level release criteria: the incoming Tamoxifen Citrate API is subjected to HPLC identity and potency analysis referenced against a certified standard, the data is logged to a batch record exclusive to this SKU, and the finished 20 mg tablets are re-assessed by HPLC after GMP-certified compression to confirm that per-tablet content integrity has been preserved through the mechanical tableting process. The 50-tablet blister format itself is part of Hilma Biocare's presentation architecture for oral solid-dose products — a configuration chosen to maintain tablet integrity and protect against moisture ingress across the product's stated shelf life. Each sealed pack carries a batch-specific lot code that links the physical unit back to its corresponding analytical dossier, enabling downstream verification without dependence on a shared portfolio certificate. This structure is particularly relevant for a 20 mg high-denomination tablet where confirmed per-unit potency is operationally critical for practitioners running precisely dosed multi-phase PCT regimens.